Avoided cost in chemotherapy drugs by patient inclusion in clinical trials.

e17544 Background: To determine the direct economic impact attributable to drugs assigned to patients (pts) enrolled in clinical trials (CT) by the medical oncology department of a third level hospital in terms of avoided cost. Methods: Avoided cost: value of drugs that pts included in CT should have received by protocol and that the hospital must not pay because are provided by the CT promoter or because they are replaced by investigational drugs. Retrospective observational study (January 2004 - December 2013). Collecting data from records of CT conducted by the Medical Oncology Department during the study period. Included all CT initiated during the study period with marketed drugs on off-label therapeutic indications for Clinical Research and CT made with no marketed drugs for indications with available alternatives. Avoided cost is calculated on average body surface of pts included in each study. The cost of treatment per pt: per mg of active principle/m2 or per dosage unit as applied. The cost calcu...